{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-003421","form_type":"8-K","ticker":null,"cik":"0000316253","company_name":"ENZO BIOCHEM INC","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.945987+00:00","generated_at":"2026-05-28T02:27:11.891400+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Enzo Biochem receives NYSE non-compliance notices for low market cap & stock price","bullets":["NYSE notified Enzo of non-compliance due to 30-day avg market cap <$50M and equity <$50M (Oct 31, 2024).","Additionally, average closing price of ENZ common stock was <$1.00 over consecutive 30 trading days.","Company has 18 months to cure market cap/equity deficiency and 6 months to cure price deficiency.","Enzo will notify NYSE by Jan 23, 2025 and submit a compliance plan by Feb 21, 2025.","Common stock continues to trade on NYSE subject to other listing standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-003421","json":"https://secwatch.observer/filing/0001213900-25-003421.json","markdown":"https://secwatch.observer/filing/0001213900-25-003421.md","text":"https://secwatch.observer/filing/0001213900-25-003421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/ea022765801-8k_enzobiochem.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:27:11.891400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c751a1b777842073f29d328770b16ccbc6dca3a","claim":"ENZO BIOCHEM INC received a nyse deficiency notice notice regarding market value (rules 802.01B).","evidence_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","confidence":0.9},{"claim_id":"8223b730a8264e58274e4a9f8880ad0a4f0e9336","claim":"ENZO BIOCHEM INC received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).","evidence_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received\na letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section\n802.01B of the NYSE Listed Company Ma","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001493152-26-025629","ticker":"CDT","company_name":"CDT Equity Inc.","filed_at":"2026-05-28T20:30:30+00:00","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025629","json":"https://secwatch.observer/filing/0001493152-26-025629.json","markdown":"https://secwatch.observer/filing/0001493152-26-025629.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received\na letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section\n802.01B of the NYSE Listed Company Ma","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","comparable_excerpt":"May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing\nQualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with\nNasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report\non Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued\nlisting on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm"}},{"accession":"0001213900-26-061545","ticker":"CHAR","company_name":"Charlton Aria Acquisition Corp","filed_at":"2026-05-27T20:41:44+00:00","headline":"Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061545","json":"https://secwatch.observer/filing/0001213900-26-061545.json","markdown":"https://secwatch.observer/filing/0001213900-26-061545.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/ea0292193-8k_charlton.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received\na letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section\n802.01B of the NYSE Listed Company Ma","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","comparable_excerpt":"May 22, 2026, Charlton\nAria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm"}},{"accession":"0001493152-26-025277","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-05-26T21:18:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late quarterly and annual filings","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025277","json":"https://secwatch.observer/filing/0001493152-26-025277.json","markdown":"https://secwatch.observer/filing/0001493152-26-025277.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received\na letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section\n802.01B of the NYSE Listed Company Ma","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","comparable_excerpt":"May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying\nit that Nasdaq has initiated a process which could result in the delisting of the Company’s secu","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm"}},{"accession":"0001836875-26-000036","ticker":"NVVE","company_name":"Nuvve Holding Corp.","filed_at":"2026-05-22T22:35:13+00:00","headline":"Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001836875-26-000036","json":"https://secwatch.observer/filing/0001836875-26-000036.json","markdown":"https://secwatch.observer/filing/0001836875-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/nvve-20260522.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received\na letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section\n802.01B of the NYSE Listed Company Ma","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","comparable_excerpt":"May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm"}},{"accession":"0001213900-26-054565","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-11T21:09:36+00:00","headline":"AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal","event_type":"regulatory","sec_items":["3.01","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054565","json":"https://secwatch.observer/filing/0001213900-26-054565.json","markdown":"https://secwatch.observer/filing/0001213900-26-054565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/0001213900-26-054565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/ea0290063-8k_allied.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received\na letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section\n802.01B of the NYSE Listed Company Ma","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","comparable_excerpt":"termination\nbefore an independent Hearings Panel (the “Panel”) by May 13, 2026. On November 4, 2025, Staff notified the Company\nthat the bid price of the Common Stock had closed at less than $1.00 per share over 30 consecutive business days, and, as a result, did\nnot comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Staff Determination was issued pursuant\nto Nasdaq Listing Rule 5810(c)(3)(A) on the grounds that the Company has not regained compliance with the Minimum Bid Price Rule during\na 180-day compliance period and is not eligible for a second 180-day complian","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/0001213900-26-054565-index.htm"}},{"accession":"0001731122-26-000668","ticker":"SBEV","company_name":"SPLASH BEVERAGE GROUP, INC.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M","event_type":"regulatory","sec_items":["1.01","1.02","3.01","3.02","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000668","json":"https://secwatch.observer/filing/0001731122-26-000668.json","markdown":"https://secwatch.observer/filing/0001731122-26-000668.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/e7604_8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received\na letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section\n802.01B of the NYSE Listed Company Ma","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","comparable_excerpt":"April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”)\nthat the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined\nin Section 1","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm"}},{"accession":"0001493152-26-019609","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-04-29T23:59:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late 10-K filing; may submit compliance plan by May 18, 2026","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-019609","json":"https://secwatch.observer/filing/0001493152-26-019609.json","markdown":"https://secwatch.observer/filing/0001493152-26-019609.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226019609/0001493152-26-019609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226019609/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 8, 2025 Enzo Biochem, Inc. (the “Company”) received\na letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section\n802.01B of the NYSE Listed Company Ma","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390025003421/0001213900-25-003421-index.htm","comparable_excerpt":"April 23, 2026, Vestand Inc. (the “Company”) received a staff deficiency notice (the “Notice”) from The Nasdaq\nStock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-K for the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226019609/0001493152-26-019609-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}